HER2 Inhibitor CP-724,714 — drug

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	0	0	0	2	0	—	—	2003-01
Malignant Breast Neoplasm	Phase1	Phase 1	0	0	0	1	0	—	—	2003-01

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 18 hours agoSource updated unknown

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB3 Overexpression1
Gefitinib + HER2 Inhibitor CP-724,714

Clinical trials

Trials with this intervention (2)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–2 of 2 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00055926	CP-724,714 in Treating Patients With Metastatic Breast Cancer	completed	Phase 1	9	Jonsson Comprehensive Cancer CenterOTHER	1	Aug 3, 2020	clinicaltrials
NCT00102895	A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer	terminated	Phase 2